Harrison.ai has petitioned the FDA to exempt some radiology AI devices from premarket review, prompting mixed feedback from industry stakeholders.
Key Details
- 1Harrison.ai seeks FDA exemption for certain computer-aided detection (CAD) AI devices from premarket review.
- 2The company argues current US regulatory pathways are too burdensome for rapidly evolving AI.
- 3Stakeholder comments included feedback from RSNA, ACR, and Patient Alliance for Safe Imaging.
- 4ACR emphasized the need to prioritize patient safety and warned against unintended safety risks.
- 5Harrison.ai has 8 FDA clearances covering 12 indications and its products serve over 1,000 facilities in 40 countries.
- 6Consulting firm Rubrum Advising submitted the petition in October 2023.
Why It Matters
If granted, this exemption could significantly alter the regulatory landscape for radiology AI software, balancing innovation access against patient safety concerns. The decision will set a precedent for future AI device oversight in imaging.
Source
Radiology Business
Related News
•Radiology Business
NCCN Endorses AI Risk Tools for Breast Cancer Screening
NCCN's 2026 guidelines recommend routine integration of AI-based 5-year breast cancer risk prediction from mammograms.
•Radiology Business
ACR Expands Resources for Radiology Practices to Assess Imaging AI
The ACR is offering new tools to help radiology practices evaluate and monitor imaging AI algorithms.
•AuntMinnie
FDA Rejects Petition to Exempt Radiology AI Devices from 510(k) Review
FDA denies a petition to exempt certain radiology AI software from 510(k) review, stressing ongoing regulatory oversight.